TABLE 1.
Straina | EC50 (μM)b
|
||||||
---|---|---|---|---|---|---|---|
AZT | ddI | d4T | PMPA | 3TC | FTC | ABC | |
HIV-1NL4-3 (wt) | 0.16 ± 0.07 (1) | 4.7 ± 2.9 (1) | 5.5 ± 1.6 (1) | 7.2 ± 2.0 (1) | 0.88 ± 0.29 (1) | 0.27 ± 0.11 (1) | 7.6 ± 3.0 (1) |
HIV-1NL4-3 Q151M+4 variantc | 7.0 ± 3.4 (43) | 45 ± 17 (10) | 79 ± 42 (14) | 26 ± 11 (4) | 3.7 ± 3.0 (4) | 0.79 ± 0.10 (3) | 40 ± 24 (5) |
HIV-2ROD (wt) | 0.12 ± 0.06 (1) | 8.0 ± 5.5 (2) | 7.1 ± 3.7 (1) | 7.2 ± 3.8 (1) | 2.0 ± 1.2 (2) | 0.50 ± 0.14 (2) | 7.2 ± 2.1 (1) |
Viruses produced with full-length plasmid clones of HIV-1NL4-3 (pR9ΔApa) (23) or HIV-2ROD (pROD9) (7). Infectivities of wild-type (wt) HIV-1NL4-3 and the Q151M+4 variant of HIV-1NL4-3 were 6,300 ± 2,000 and 4,500 ± 2,000 FFU/ng HIV-1 capsid p24, respectively (means ± standard errors of the means). The infectivity of wild-type HIV-2ROD was 15 ± 9 FFU/ng HIV-2 capsid p26.
EC50s were obtained with MAGIC-5A cells as previously described (22). The values shown in bold are significantly different from values for wild-type HIV-1NL4-3 (P < 0.05; analysis of variance of log[EC50] values by use of Tukey's multiple-comparison test). The numbers in parentheses indicate n-fold changes in the EC50s relative to that for wild-type HIV-1NL4-3. EC50s are the means ± the standard deviations from four or more independent experiments. ddI, didanosine; d4T, stavudine; PMPA, tenofovir; ABC, abacavir.
Multinucleoside-resistant mutant (10).